Back to search

Article

Receptor-binding domain recombinant protein on alum-CpG induces broad protection against SARS-CoV-2 variants of concern

2021-07-07

Abstract excerpt

We conducted preclinical studies in mice using a yeast-produced SARS-CoV-2 RBD subunit vaccine candidate formulated with aluminum hydroxide (alum) and CpG deoxynucleotides. This formulation is equivalent to the CorbevaxTM vaccine that recently received emergency use authorization by the Drugs Controller General of India. We compared the immune response of mice vaccinated with RBD/alum to mice vaccinated with RBD/a...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work
dc6ff5c7-9ca9-50ae-9bfa-ac08387f3ed1
DOI
10.1101/2021.07.06.451353
Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest
Interactive article relationship graphSelect a related publication card to move it into the centre and load its closest explainable connections. Solid lines are source-backed structured connections. Dashed lines are semantic discovery signals and are not scientific evidence.
Receptor-binding domain recombinant protein on alum-CpG induces broad protection against SARS-CoV-2 variants of concernDOI 10.1101/2021.07.06.451353
Receptor-binding domain recombinant protein on alum-CpG induces broad protection against SARS-CoV-2 variants of concernSemantic proximity
Alum:CpG adjuvant enables SARS-CoV-2 RBD-induced protection in aged mice and synergistic activation of human elder type 1 immunitySemantic proximity
Broad immunity to SARS-CoV-2 variants of concern mediated by a SARS-CoV-2 receptor-binding domain protein vaccineSemantic proximity
A Recombinant Protein XBB.1.5 RBD/Alum/CpG Vaccine Elicits High Neutralizing Antibody Titers against Omicron Subvariants of SARS-CoV-2Semantic proximity
Preclinical evaluation of a COVID-19 vaccine candidate based on a recombinant RBD fusion heterodimer of SARS-CoV-2Semantic proximity
Broad immunity to SARS-CoV-2 variants of concern mediated by a SARS-CoV-2 receptor-binding domain protein vaccineSemantic proximity
Safety, tolerability, and immunogenicity of a new SARS-CoV-2 recombinant Gamma variant RBD-based protein adjuvanted vaccine, used as heterologous booster in healthy adults: a Phase 1 interim reportSemantic proximity
A modular protein subunit vaccine candidate produced in yeast confers protection against SARS-CoV-2 in non-human primatesSemantic proximity
Preclinical evaluation of a COVID-19 vaccine candidate based on a recombinant RBD fusion heterodimer of SARS-CoV-2Semantic proximity
Protection of the receptor binding domain (RBD) dimer against SARS-CoV-2 and its variants.Semantic proximity
Engineered SARS-CoV-2 receptor binding domain improves manufacturability in yeast and immunogenicity in miceSemantic proximity
Efficacy of a stable multivalent broadly protective subunit vaccine platform against SARS-CoV-2 variants of concernSemantic proximity
Select a neighboring publication to make it the new centre.